Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

In vivo characterization of brain metabolism by 1 H MRS, 13 C MRS and 18 FDG PET reveals significant glucose oxidation of invasively growing glioma cells.

Lai M, Vassallo I, Lanz B, Poitry-Yamate C, Hamou MF, Cudalbu C, Gruetter R, Hegi ME.

Int J Cancer. 2018 Feb 8. doi: 10.1002/ijc.31299. [Epub ahead of print]

PMID:
29417580
2.

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.

Bady P, Kurscheid S, Delorenzi M, Gorlia T, van den Bent MJ, Hoang-Xuan K, Vauléon É, Gijtenbeek A, Enting R, Thiessen B, Chinot O, Dhermain F, Brandes AA, Reijneveld JC, Marosi C, Taphoorn MJB, Wick W, von Deimling A, French P, Stupp R, Baumert BG, Hegi ME.

Acta Neuropathol. 2018 Jan 24. doi: 10.1007/s00401-018-1810-6. [Epub ahead of print]

PMID:
29368212
3.

Ubiquitin Specific Peptidase 15 (USP15) suppresses glioblastoma cell growth via stabilization of HECTD1 E3 ligase attenuating WNT pathway activity.

Oikonomaki M, Bady P, Hegi ME.

Oncotarget. 2017 Nov 30;8(66):110490-110502. doi: 10.18632/oncotarget.22798. eCollection 2017 Dec 15.

4.

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.

Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran DD, Brem S, Hottinger AF, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Burna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z.

JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718.

5.

Glioma epigenetics: From subclassification to novel treatment options.

Gusyatiner O, Hegi ME.

Semin Cancer Biol. 2017 Nov 21. pii: S1044-579X(17)30258-4. doi: 10.1016/j.semcancer.2017.11.010. [Epub ahead of print] Review.

PMID:
29170066
6.

Evidence-based management of adult patients with diffuse glioma - Authors' reply.

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Rhun EL, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Gliomas.

Lancet Oncol. 2017 Aug;18(8):e430-e431. doi: 10.1016/S1470-2045(17)30515-6. Epub 2017 Jul 26. No abstract available.

PMID:
28759377
7.

Correlation of immune phenotype with IDH mutation in diffuse glioma.

Berghoff AS, Kiesel B, Widhalm G, Wilhelm D, Rajky O, Kurscheid S, Kresl P, Wöhrer A, Marosi C, Hegi ME, Preusser M.

Neuro Oncol. 2017 Oct 19;19(11):1460-1468. doi: 10.1093/neuonc/nox054.

PMID:
28531337
8.

European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Gliomas.

Lancet Oncol. 2017 Jun;18(6):e315-e329. doi: 10.1016/S1470-2045(17)30194-8. Epub 2017 May 5. Review. Erratum in: Lancet Oncol. 2017 Nov;18(11):e642.

PMID:
28483413
9.

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.

Blumenthal DT, Gorlia T, Gilbert MR, Kim MM, Burt Nabors L, Mason WP, Hegi ME, Zhang P, Golfinopoulos V, Perry JR, Hyun Nam D, Erridge SC, Corn BW, Mirimanoff RO, Brown PD, Baumert BG, Mehta MP, van den Bent MJ, Reardon DA, Weller M, Stupp R.

Neuro Oncol. 2017 Aug 1;19(8):1119-1126. doi: 10.1093/neuonc/nox025.

PMID:
28371907
10.

Current management of low-grade gliomas.

Hottinger AF, Hegi ME, Baumert BG.

Curr Opin Neurol. 2016 Dec;29(6):782-788. Review.

PMID:
27676279
11.

Early detection of human glioma sphere xenografts in mouse brain using diffusion MRI at 14.1 T.

Porcari P, Hegi ME, Lei H, Hamou MF, Vassallo I, Capuani S, Gruetter R, Mlynarik V.

NMR Biomed. 2016 Nov;29(11):1577-1589. doi: 10.1002/nbm.3610. Epub 2016 Sep 15.

PMID:
27717037
12.

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJ, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JM, Rossiter JP, Dif N, Balana C, Bravo-Marques J, Clement PM, Marosi C, Tzuk-Shina T, Nordal RA, Rees J, Lacombe D, Mason WP, Stupp R.

Lancet Oncol. 2016 Nov;17(11):1521-1532. doi: 10.1016/S1470-2045(16)30313-8. Epub 2016 Sep 27.

13.

Reply to F. Felix et al and M.F. Fay et al.

Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon DA, Perry JR, Mehta MP, Stupp R, Weller M.

J Clin Oncol. 2016 Sep 1;34(25):3107-8. doi: 10.1200/JCO.2016.68.0926. Epub 2016 Jun 13. No abstract available.

14.

Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).

Wick W, Gorlia T, Bady P, Platten M, van den Bent MJ, Taphoorn MJ, Steuve J, Brandes AA, Hamou MF, Wick A, Kosch M, Weller M, Stupp R, Roth P, Golfinopoulos V, Frenel JS, Campone M, Ricard D, Marosi C, Villa S, Weyerbrock A, Hopkins K, Homicsko K, Lhermitte B, Pesce G, Hegi ME.

Clin Cancer Res. 2016 Oct 1;22(19):4797-4806. Epub 2016 May 3.

15.

Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors.

Bady P, Delorenzi M, Hegi ME.

J Mol Diagn. 2016 May;18(3):350-361. doi: 10.1016/j.jmoldx.2015.11.009. Epub 2016 Feb 27.

PMID:
26927331
16.

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.

Weller M, Nabors LB, Gorlia T, Leske H, Rushing E, Bady P, Hicking C, Perry J, Hong YK, Roth P, Wick W, Goodman SL, Hegi ME, Picard M, Moch H, Straub J, Stupp R.

Oncotarget. 2016 Mar 22;7(12):15018-32. doi: 10.18632/oncotarget.7588.

17.

Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.

Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon DA, Perry JR, Mehta MP, Stupp R, Weller M.

J Clin Oncol. 2016 Mar 1;34(7):731-9. doi: 10.1200/JCO.2015.63.6563. Epub 2016 Jan 19.

18.

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.

Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z.

JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669.

PMID:
26670971
19.

Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact.

Sathyan P, Zinn PO, Marisetty AL, Liu B, Kamal MM, Singh SK, Bady P, Lu L, Wani KM, Veo BL, Gumin J, Kassem DH, Robinson F, Weng C, Baladandayuthapani V, Suki D, Colman H, Bhat KP, Sulman EP, Aldape K, Colen RR, Verhaak RG, Lu Z, Fuller GN, Huang S, Lang FF, Sawaya R, Hegi M, Majumder S.

J Neurosci. 2015 Nov 11;35(45):15097-112. doi: 10.1523/JNEUROSCI.1265-15.2015.

20.

Genome-wide DNA methylation detection by MethylCap-seq and Infinium HumanMethylation450 BeadChips: an independent large-scale comparison.

De Meyer T, Bady P, Trooskens G, Kurscheid S, Bloch J, Kros JM, Hainfellner JA, Stupp R, Delorenzi M, Hegi ME, Van Criekinge W.

Sci Rep. 2015 Oct 20;5:15375. doi: 10.1038/srep15375.

21.

The eNanoMapper database for nanomaterial safety information.

Jeliazkova N, Chomenidis C, Doganis P, Fadeel B, Grafström R, Hardy B, Hastings J, Hegi M, Jeliazkov V, Kochev N, Kohonen P, Munteanu CR, Sarimveis H, Smeets B, Sopasakis P, Tsiliki G, Vorgrimmler D, Willighagen E.

Beilstein J Nanotechnol. 2015 Jul 27;6:1609-34. doi: 10.3762/bjnano.6.165. eCollection 2015.

22.

Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?

Hegi ME, Stupp R.

Neuro Oncol. 2015 Nov;17(11):1425-7. doi: 10.1093/neuonc/nov198. Epub 2015 Sep 15. No abstract available.

23.

WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1.

Vassallo I, Zinn P, Lai M, Rajakannu P, Hamou MF, Hegi ME.

Oncogene. 2016 Jan 7;35(1):12-21. doi: 10.1038/onc.2015.61. Epub 2015 Mar 16.

PMID:
25772239
24.

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.

Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam DH, Mazurkiewicz M, Salacz M, Ashby L, Zagonel V, Depenni R, Perry JR, Hicking C, Picard M, Hegi ME, Lhermitte B, Reardon DA.

Neuro Oncol. 2015 May;17(5):708-17. doi: 10.1093/neuonc/nou356. Epub 2015 Mar 11.

25.

Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma.

Kurscheid S, Bady P, Sciuscio D, Samarzija I, Shay T, Vassallo I, Criekinge WV, Daniel RT, van den Bent MJ, Marosi C, Weller M, Mason WP, Domany E, Stupp R, Delorenzi M, Hegi ME.

Genome Biol. 2015 Jan 27;16:16. doi: 10.1186/s13059-015-0583-7.

26.

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.

Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wöhrer A, Dieckmann K, Filipits M, Brandstetter A, Weller M, Kurscheid S, Hegi ME, Zielinski CC, Marosi C, Hainfellner JA, Preusser M, Wick W.

Neuro Oncol. 2015 Aug;17(8):1064-75. doi: 10.1093/neuonc/nou307. Epub 2014 Oct 29.

27.

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M; European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium; CENTRIC study team.

Lancet Oncol. 2014 Sep;15(10):1100-8. doi: 10.1016/S1470-2045(14)70379-1. Epub 2014 Aug 19.

28.

MGMT testing--the challenges for biomarker-based glioma treatment.

Wick W, Weller M, van den Bent M, Sanson M, Weiler M, von Deimling A, Plass C, Hegi M, Platten M, Reifenberger G.

Nat Rev Neurol. 2014 Jul;10(7):372-85. doi: 10.1038/nrneurol.2014.100. Epub 2014 Jun 10. Review.

29.

Reply to M.C. Chamberlain.

Gilbert MR, Dignam J, Pugh S, Armstrong TS, Wefel JS, Aldape K, Stupp R, Hegi M, Won M, Curran WJ, Mehta MP.

J Clin Oncol. 2014 May 20;32(15):1634-5. doi: 10.1200/JCO.2013.54.9717. Epub 2014 Apr 21. No abstract available.

30.

Molecular insights into brain tumors: ready for translation into novel treatment strategies?

Hegi ME.

Curr Opin Neurol. 2013 Dec;26(6):678-80. doi: 10.1097/WCO.0000000000000038. No abstract available.

PMID:
24152816
31.

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ Jr, Mehta MP.

J Clin Oncol. 2013 Nov 10;31(32):4085-91. doi: 10.1200/JCO.2013.49.6968. Epub 2013 Oct 7.

32.

Molecular neuro-oncology in clinical practice: a new horizon.

Weller M, Pfister SM, Wick W, Hegi ME, Reifenberger G, Stupp R.

Lancet Oncol. 2013 Aug;14(9):e370-9. doi: 10.1016/S1470-2045(13)70168-2. Review. Erratum in: Lancet Oncol. 2015 May;16(5):e199.

33.

Neuro-oncology: in search of molecular markers of glioma in elderly patients.

Hegi ME, Stupp R.

Nat Rev Neurol. 2013 Aug;9(8):424-5. doi: 10.1038/nrneurol.2013.127. Epub 2013 Jul 2. No abstract available.

PMID:
23817351
34.

Brain cancer in 2012: Molecular characterization leads the way.

Stupp R, Hegi ME.

Nat Rev Clin Oncol. 2013 Feb;10(2):69-70. doi: 10.1038/nrclinonc.2012.240. Epub 2013 Jan 8. Review. No abstract available.

PMID:
23296110
35.

The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.

Johannessen TC, Prestegarden L, Grudic A, Hegi ME, Tysnes BB, Bjerkvig R.

Neuro Oncol. 2013 Mar;15(3):269-78. doi: 10.1093/neuonc/nos301. Epub 2012 Dec 20.

36.

Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.

Weller M, Stupp R, Hegi ME, van den Bent M, Tonn JC, Sanson M, Wick W, Reifenberger G.

Neuro Oncol. 2012 Sep;14 Suppl 4:iv100-8. doi: 10.1093/neuonc/nos206. Review.

37.

EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.

Franceschi E, Stupp R, van den Bent MJ, van Herpen C, Laigle Donadey F, Gorlia T, Hegi M, Lhermitte B, Strauss LC, Allgeier A, Lacombe D, Brandes AA.

Neuro Oncol. 2012 Dec;14(12):1503-10. doi: 10.1093/neuonc/nos256. Epub 2012 Oct 22.

38.

Epidermal growth factor receptor: a re-emerging target in glioblastoma.

Hegi ME, Rajakannu P, Weller M.

Curr Opin Neurol. 2012 Dec;25(6):774-9. doi: 10.1097/WCO.0b013e328359b0bc. Review.

PMID:
23007009
39.

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R; Nordic Clinical Brain Tumour Study Group (NCBTSG).

Lancet Oncol. 2012 Sep;13(9):916-26. Epub 2012 Aug 8.

PMID:
22877848
40.

A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signature.

Zinn PO, Sathyan P, Mahajan B, Bruyere J, Hegi M, Majumder S, Colen RR.

PLoS One. 2012;7(8):e41522. doi: 10.1371/journal.pone.0041522. Epub 2012 Aug 3.

41.

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.

Bady P, Sciuscio D, Diserens AC, Bloch J, van den Bent MJ, Marosi C, Dietrich PY, Weller M, Mariani L, Heppner FL, Mcdonald DR, Lacombe D, Stupp R, Delorenzi M, Hegi ME.

Acta Neuropathol. 2012 Oct;124(4):547-60. doi: 10.1007/s00401-012-1016-2. Epub 2012 Jul 19. Erratum in: Acta Neuropathol. 2013 Jul;126(1):159.

42.

DNA fingerprinting of glioma cell lines and considerations on similarity measurements.

Bady P, Diserens AC, Castella V, Kalt S, Heinimann K, Hamou MF, Delorenzi M, Hegi ME.

Neuro Oncol. 2012 Jun;14(6):701-11. doi: 10.1093/neuonc/nos072. Epub 2012 May 8.

43.

A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).

Nabors LB, Mikkelsen T, Hegi ME, Ye X, Batchelor T, Lesser G, Peereboom D, Rosenfeld MR, Olsen J, Brem S, Fisher JD, Grossman SA; New Approaches to Brain Tumor Therapy (NABTT) Central Nervous System Consortium.

Cancer. 2012 Nov 15;118(22):5601-7. doi: 10.1002/cncr.27585. Epub 2012 Apr 19.

44.

New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials.

Gorlia T, Stupp R, Brandes AA, Rampling RR, Fumoleau P, Dittrich C, Campone MM, Twelves CC, Raymond E, Hegi ME, Lacombe D, van den Bent MJ.

Eur J Cancer. 2012 May;48(8):1176-84. doi: 10.1016/j.ejca.2012.02.004. Epub 2012 Mar 28.

PMID:
22464345
45.

Clinical implications of molecular neuropathology and biomarkers for malignant glioma.

Tabatabai G, Hegi M, Stupp R, Weller M.

Curr Neurol Neurosci Rep. 2012 Jun;12(3):302-7. doi: 10.1007/s11910-012-0263-x. Review.

PMID:
22427102
46.

Individualized targeted therapy for glioblastoma: fact or fiction?

Weller M, Stupp R, Hegi M, Wick W.

Cancer J. 2012 Jan-Feb;18(1):40-4. doi: 10.1097/PPO.0b013e318243f6c9. Review.

PMID:
22290256
47.

Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.

Hegi ME, Janzer RC, Lambiv WL, Gorlia T, Kouwenhoven MC, Hartmann C, von Deimling A, Martinet D, Besuchet Schmutz N, Diserens AC, Hamou MF, Bady P, Weller M, van den Bent MJ, Mason WP, Mirimanoff RO, Stupp R, Mokhtari K, Wesseling P; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group.

Acta Neuropathol. 2012 Jun;123(6):841-52. doi: 10.1007/s00401-011-0938-4. Epub 2012 Jan 15.

48.

Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.

Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M, Carlson BL, Sarkaria JN, Margison GP, Aldape K, Hawkins C, Hegi M, Guha A.

J Clin Invest. 2012 Jan;122(1):253-66. doi: 10.1172/JCI59334. Epub 2011 Dec 12. Erratum in: J Clin Invest. 2012 Feb 1;122(2):782.

49.

Current concepts and management of glioblastoma.

Preusser M, de Ribaupierre S, Wöhrer A, Erridge SC, Hegi M, Weller M, Stupp R.

Ann Neurol. 2011 Jul;70(1):9-21. doi: 10.1002/ana.22425. Review.

PMID:
21786296
50.

The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence.

Lambiv WL, Vassallo I, Delorenzi M, Shay T, Diserens AC, Misra A, Feuerstein B, Murat A, Migliavacca E, Hamou MF, Sciuscio D, Burger R, Domany E, Stupp R, Hegi ME.

Neuro Oncol. 2011 Jul;13(7):736-47. doi: 10.1093/neuonc/nor036. Epub 2011 Jun 3.

Supplemental Content

Support Center